Speeding up the evaluation of new agents in cancer

MKB Parmar; FMS Barthel; M Sydes; R Langley; R Kaplan; E Eisenhauer; M Brady; Nicholas James; MA Bookman; AM Swart; W Qian; P Royston

doi:10.1093/jnci/djn267

Speeding up the evaluation of new agents in cancer

MKB Parmar, FMS Barthel, M Sydes, R Langley, R Kaplan, E Eisenhauer, M Brady, Nicholas James, MA Bookman, AM Swart, W Qian, P Royston

Cancer Clinical Trials Unit

Research output: Contribution to journal › Editorial

95 Citations (Scopus)

Abstract

Despite both the increase in basic biologic knowledge and the fact that many new agents have reached various stages of development during the last 10 years, the number of new treatments that have been approved for patients has not increased as expected. We propose the multi-arm, multi-stage trial design as a way to evaluate treatments faster and more efficiently than current standard trial designs. By using intermediate outcomes and testing a number of new agents (and combinations) simultaneously, the new design requires fewer patients. Three trials using this methodology are presented.

Original language	English
Pages (from-to)	1204-1214
Number of pages	11
Journal	Journal of the National Cancer Institute
Volume	100
Issue number	17
DOIs	https://doi.org/10.1093/jnci/djn267
Publication status	Published - 1 Sept 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jnci/djn267

Cite this

@article{79a041aa16a64b60a99eb072c0058a3d,

title = "Speeding up the evaluation of new agents in cancer",

abstract = "Despite both the increase in basic biologic knowledge and the fact that many new agents have reached various stages of development during the last 10 years, the number of new treatments that have been approved for patients has not increased as expected. We propose the multi-arm, multi-stage trial design as a way to evaluate treatments faster and more efficiently than current standard trial designs. By using intermediate outcomes and testing a number of new agents (and combinations) simultaneously, the new design requires fewer patients. Three trials using this methodology are presented.",

author = "MKB Parmar and FMS Barthel and M Sydes and R Langley and R Kaplan and E Eisenhauer and M Brady and Nicholas James and MA Bookman and AM Swart and W Qian and P Royston",

year = "2008",

month = sep,

day = "1",

doi = "10.1093/jnci/djn267",

language = "English",

volume = "100",

pages = "1204--1214",

journal = "Journal of the National Cancer Institute",

issn = "1460-2105",

publisher = "Oxford University Press",

number = "17",

}

TY - JOUR

T1 - Speeding up the evaluation of new agents in cancer

AU - Parmar, MKB

AU - Barthel, FMS

AU - Sydes, M

AU - Langley, R

AU - Kaplan, R

AU - Eisenhauer, E

AU - Brady, M

AU - James, Nicholas

AU - Bookman, MA

AU - Swart, AM

AU - Qian, W

AU - Royston, P

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Despite both the increase in basic biologic knowledge and the fact that many new agents have reached various stages of development during the last 10 years, the number of new treatments that have been approved for patients has not increased as expected. We propose the multi-arm, multi-stage trial design as a way to evaluate treatments faster and more efficiently than current standard trial designs. By using intermediate outcomes and testing a number of new agents (and combinations) simultaneously, the new design requires fewer patients. Three trials using this methodology are presented.

AB - Despite both the increase in basic biologic knowledge and the fact that many new agents have reached various stages of development during the last 10 years, the number of new treatments that have been approved for patients has not increased as expected. We propose the multi-arm, multi-stage trial design as a way to evaluate treatments faster and more efficiently than current standard trial designs. By using intermediate outcomes and testing a number of new agents (and combinations) simultaneously, the new design requires fewer patients. Three trials using this methodology are presented.

U2 - 10.1093/jnci/djn267

DO - 10.1093/jnci/djn267

M3 - Editorial

C2 - 18728279

SN - 1460-2105

VL - 100

SP - 1204

EP - 1214

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 17

ER -

Speeding up the evaluation of new agents in cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this